Cartesian Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $203.0M
- Price
- $6.71
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.45%
- Volume
- 84.4K
About
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Quick stats
Shares outstanding30.3M
Computed float10.2M
Float / shares33.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001453687
AI Summary
AI-generated1/14
minorneutralother
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics granted inducement stock options to purchase 121,900 shares to four new employees, with an exercise price of $7.22 matching the Nasdaq closing price on the October 1, 2026 grant date.
The grants were made under Nasdaq Rule 5635(c)(4) via the company's 2018 Employment Inducement Incentive Award Plan, vesting over four years with a ten-year term.
This is routine hiring-related compensation disclosure with no bearing on clinical programs such as Descartes-08.